Abcam, ab320075, Anti SARS-CoV-2 Spike Glycoprotein S1 [Omi2-18] BSA and Azide Free

Size: 100µg / 1mg
Human Recombinant Monoclonal SPIKE antibody. Carrier free. Suitable for I-ELISA and reacts with SARS-CoV-2 samples.
Key facts
Host species:Human,
Clonality:Monoclonal,
Clone number:Omi2-18,
Isotype:IgG1,
Carrier free:Yes,
Reacts with:SARS-CoV-2,
Applications:I-ELISASee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab320075 is the carrier-free version of
ab320074
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: 100% PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The SARS-CoV-2 Spike Glycoprotein also known as COVID-19 Spike Protein is a trimeric protein weighing approximately 180-200 kDa. It is located on the surface of the SARS-CoV-2 virus playing an important role in virus infectivity. The protein comprises two main subunits S1 and S2 which facilitate attachment to and fusion with host cells. The S1 subunit contains the receptor binding domain (RBD) which specifically binds to the human angiotensin-converting enzyme 2 (ACE2) receptor. The Spike Glycoprotein is expressed in infected host cells mainly in the respiratory tract allowing the virus to enter and initiate replication.
Biological function summary
The SARS-CoV-2 Spike Glycoprotein initiates viral entry by interacting with the host cell's ACE2 receptor which leads to viral fusion and entry into the cell's cytoplasm. The protein is part of the virion structure and forms the visible spike on the virion's surface. Upon binding a conformational change triggers the fusion of viral and cellular membranes a vital step for the viral lifecycle. The multimeric nature of the Spike Protein facilitates its interaction with antibodies including those known as 'anti-spike antibodies' which can neutralize the virus and prevent cell infection.
Pathways
The Spike Glycoprotein plays a significant role in the viral infection process and immune response pathways. It is central to the receptor-mediated endocytosis pathway where the virus is internalized into host cells. The protein’s interaction with ACE2 modifies downstream signaling pathways potentially altering host cell functions. Related proteins in these pathways include the ACE2 receptor and the cellular protease TMPRSS2 which primes the Spike Protein for fusion and viral entry.
The Spike Glycoprotein is chiefly implicated in COVID-19 the disease caused by SARS-CoV-2. The interaction with ACE2 is not just vital for infection but also contributes to the disease's symptomatology as ACE2 is involved in regulating blood pressure and inflammation. Additionally the Spike Protein's role in viral entry makes it a target for therapeutic interventions including 'anti-spike antibodies' and vaccines aimed at blocking this process to prevent infection. The protein's relevance to COVID-19 has led to significant interest in developing diagnostic and therapeutic tools such as 'antibodies COVID' that target the Spike Glycoprotein to manage the disease effectively.